18 children and young adults have been hospitalized in the state of Connecticut for heart-related issues after receiving the COVID-19 vaccine, less than a week after the Center for Disease Control opened an investigation into cases of myocarditis (heart inflammation) linked to COVID vaccinations in young people and vaccinations.
During a press conference on Monday, state acting health commissioner Deidre Gifford stated, “All of the cases that were reported to us were hospitalized, the vast majority for a couple of days. One individual that we’re aware of is still hospitalized. The other 17 have been sent home and they’re doing fine.”
According to Gifford, 16 of the 17 patients have been released from hospitals, with one remaining under watch. “One individual that we’re aware of is still hospitalized,” Guifford said. “The other 17 have been sent home and they’re doing fine.”
As National File previously reported, the CDC has opened an investigation into cases of myocarditis reported in young people who have recently taken the COVID vaccine. Social media platform Twitter tried to censor National File’s reporting, calling it misleading, but linked to the CDC – the primary source for the report – in its rebuttal, proving the story’s accuracy.
National File’s reporting on the CDC investigation can be read in part below:
“The Advisory Committee on Immunization Practices (ACIP) COVID-19 Vaccine Safety Technical (VaST) Work Group has reviewed post-authorization COVID-19 vaccine safety data on a weekly basis since the start of the U.S. vaccination program,” the CDC said in a statement.
“The VaST session on May 17, 2021, included several presentations on myocarditis following mRNA vaccines, from the Department of Defense (DoD), the Vaccine Adverse Event Reporting System (VAERS), and Vaccine Safety Datalink (VSD),” the statement continued. “There were also brief updates from the Veteran’s Administration (VA) and the Clinical Immunization Safety Assessment (CISA) groups about their plans for future investigation of myocarditis.”
The report noted that reports of vaccine-induced myocarditis have occurred “predominantly in adolescents and young adults, more often in males than females, more often following dose 2 than dose 1, and typically within 4 days after vaccination.”
VaSt went on to recommend that “Further information should be collected through medical record review about potential myocarditis cases that were reported into VAERS,” “Information about this potential adverse event should be provided to clinicians to enhance early recognition and appropriate management of persons who develop myocarditis symptoms following vaccination,” and, “Collaboration between infectious diseases, cardiology, and rheumatology specialists is needed to provide guidance on diagnosis, treatment, and management of myocarditis.”
